Ascendis Pharma Releases Week 182 Data for TransCon PTH
Ascendis Pharma announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems - CNS, kidney, small intestine, and bone - as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.
